This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (80)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

E. John Gallagher, MD; Catherine M. Viscoli, PhD; Ralph I. Horwitz, MD

JAMA. 1993;270(6):742-744.

Abstract
Objective.
—To examine the relationship between adherence to a medical regimen and mortality following a myocardial infarction in women.

Design.
—Analysis of the female cohort entered into a randomized double-blind multicenter trial.

Setting.
—National Heart, Lung, and Blood Institute β-Blocker Heart Attack Trial.

Participants.
—The 602 women, aged 30 to 69 years, enrolled in the β-Blocker Heart Attack Trial.

Intervention.
—Random assignment to propranolol hydrochloride or placebo 5 to 21 days following a myocardial infarction.

Measurements.
—Adherence for each patient was calculated as the mean of all quarterly adherence estimates during the course of the trial (median follow-up, 26 months). Adherence was classified as good (taking 75% of medication) or poor (taking <75% of medication). The end point was death from all causes occurring at any time during the trial, adjusted for treatment category and other clinical and sociodemographic features.

Results.
—Adherence data were available on 505 women, of whom 32 (6.3%) died. Death occurred in 13.6% of poor adherers compared with 5.6% of good adherers (relative risk, 2.4; 95% confidence interval, 1.1 to 5.6). The effect of adherence on mortality remained undiminished after adjustment for treatment category (propranolol or placebo), age, severity of myocardial infarction, congestive heart failure, smoking history, marital status, educational level, and race (adjusted relative risk of death for poor adherers, 2.5 to 3.0; P.02).

Conclusions.
—The independent effect of adherence on mortality following a myocardial infarction in women is clinically substantial, statistically significant, and similar in magnitude to that reported earlier for men.

(JAMA. 1993;270:742-744)

Author Affiliations
From the Robert Wood Johnson Clinical Scholars Program (Dr Gallagher) and Departments of Internal Medicine (Drs Horowitz and Viscoli), Epidemiology (Dr Horowitz), and Public Health (Dr Horowitz), Yale University School of Medicine, New Haven, Conn.

Footnotes
Reprint requests to 1-W-20, Bronx Municipal Hospital, Bronx, NY 10461 (Dr Gallagher).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

{beta}-Blocker Compliance, Mortality, and Reinfarction: Validation of Clinical Trial Association Using Insurer Claims Data
Kleiner et al.
American Journal of Medical Quality 2009;24:512-519.
ABSTRACT  

Is Personality a Key Predictor of Missing Study Data? An Analysis From a Randomized Controlled Trial
Jerant et al.
Ann Fam Med 2009;7:148-156.
ABSTRACT | FULL TEXT  

Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations
Hannan
J Am Coll Cardiol Intv 2008;1:211-217.
ABSTRACT | FULL TEXT  

The Truth and Consequences of the COURAGE Trial
Kereiakes et al.
J Am Coll Cardiol 2007;50:1598-1603.
ABSTRACT | FULL TEXT  

Relationships Between Beliefs about Medications and Nonadherence to Prescribed Chronic Medications
Phatak and Thomas
The Annals of Pharmacotherapy 2006;40:1737-1742.
ABSTRACT | FULL TEXT  

Adherence to Medications by Patients After Acute Coronary Syndromes
Sud et al.
The Annals of Pharmacotherapy 2005;39:1792-1797.
ABSTRACT | FULL TEXT  

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs
Ray
Am J Epidemiol 2003;158:915-920.
ABSTRACT | FULL TEXT  

Hormone replacement therapy is associated with improved survival in women with advanced heart failure
Lindenfeld et al.
J Am Coll Cardiol 2003;42:1238-1245.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease
Humphrey et al.
ANN INTERN MED 2002;137:273-284.
ABSTRACT | FULL TEXT  

The Placebo Effect in Alternative Medicine: Can the Performance of a Healing Ritual Have Clinical Significance?
Kaptchuk
ANN INTERN MED 2002;136:817-825.
ABSTRACT | FULL TEXT  

A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy
Grady
JAMA 2002;287:2130-2137.
FULL TEXT  

Estrogen replacement therapy, atherosclerosis, and vascular function
Mikkola and Clarkson
Cardiovasc Res 2002;53:605-619.
ABSTRACT | FULL TEXT  

Hormone Therapy and In-Hospital Survival After Myocardial Infarction in Postmenopausal Women
Shlipak et al.
Circulation 2001;104:2300-2304.
ABSTRACT | FULL TEXT  

Postmenopausal hormones and heart disease
Grady and Hulley
J Am Coll Cardiol 2001;38:8-10.
FULL TEXT  

Hormones To Prevent Coronary Disease in Women: When Are Observational Studies Adequate Evidence?
Grady and Hulley
ANN INTERN MED 2000;133:999-1001.
FULL TEXT  

Discrepancies in the Use of Medications: Their Extent and Predictors in an Outpatient Practice
Bedell et al.
Arch Intern Med 2000;160:2129-2134.
ABSTRACT | FULL TEXT  

Poor Adherence to Placebo or Amiodarone Therapy Predicts Mortality: Results From the CAMIAT Study
Irvine et al.
Psychosom. Med. 1999;61:566-575.
ABSTRACT | FULL TEXT  

Hormones and Heart Disease in Women: Heart and Estrogen/Progestin Replacement Study in Perspective
Barrett-Connor and Stuenkel
J. Clin. Endocrinol. Metab. 1999;84:1848-1853.
FULL TEXT  

Non-compliance and knowledge of prescribed medication in elderly patients with heart failure
Cline et al.
Eur J Heart Fail 1999;1:145-149.
ABSTRACT | FULL TEXT  

Impact of Medication Nonadherence on Coronary Heart Disease Outcomes: A Critical Review
McDermott et al.
Arch Intern Med 1997;157:1921-1929.
ABSTRACT